At least a dozen large drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs in India, crashing prices as soon as the patent expires Friday. Natco Pharma Ltd. plans ...

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

Glenmark Pharmaceuticals has received final approval from the United States Food and Drug Administration for its Fluticasone Propionate Nasal Spray (OTC), marking its entry into the US ...

A massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide—the key ingredient behind blockbuster drugs—expires. This opens the floodgates for over 40 ...

German generics, biosimilars and consumer healthcare major STADA Arzneimittel (SAZ: Xetra) today released financial results for full year 2025. All the news that moves the needle in pharma and biotech ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

The expected arrival of generic versions of semaglutide -- the active ingredient in Ozempic and Wegovy -- is poised to force a rethink of how Canadian insurers handle obesity treatments. At present, ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.